Aim immunotech announces that the first subject is enrolled in the phase 1b/2 study evaluating ampligen® in combination with astrazeneca's imfinzi® for the treatment of late-stage pancreatic cancer

First enrollment takes place at erasmus medical center in rotterdam, netherlands first enrollment takes place at erasmus medical center in rotterdam, netherlands

AIM Ratings Summary

AIM Quant Ranking